Clinical Trial

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2011-01-20; most recent amendment 2026-01-14.
Status change: Suspended → Recruiting 2020-07-13
Status change: Recruiting → Suspended 2020-04-23
Trial Details
NCT Number NCT01280994
Lead Sponsor Bastiaan Driehuys
Conditions Interstitial Lung Disease
Enrollment 445 participants
Start Date 2011-01
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-16